FDA Approves Roivant's Lisraya for Dermatomyositis
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA approved Roivant and its subsidiary Priovant's new medicine for dermatomyositis on Thursday
- Brepocitinib, to be marketed under the brand name Lisraya, is a once-daily pill
- Dermatomyositis is characterized by muscle weakness and a painful skin rash, and affects an estimated 40,000 to 70,000 people in the U.S. (per Roivant)
- Current standard of care relies on high doses of steroids and other immune-suppressing drugs
- Roivant developed the therapy through its subsidiary Priovant, bringing an oral targeted option to a disease where steroids have long dominated treatment
Why it matters: The estimated 40,000–70,000 U.S. patients with dermatomyositis currently rely on steroids and broader immunosuppressants as first-line therapy; an FDA-approved oral alternative gives clinicians and patients a targeted option that could shift prescribing away from long-term steroid use.
Ask SkimNews
